139 related articles for article (PubMed ID: 35434283)
1. Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma.
Shaikh A; Goli K; Rich NE; Benhammou JN; Khaderi S; Hernaez R; Agopian VG; Vierling JM; Kim D; Ahmed A; Goss JA; Rana A; Kanwal F; Cholankeril G
Transplant Direct; 2022 May; 8(5):e1313. PubMed ID: 35434283
[TBL] [Abstract][Full Text] [Related]
2. Racial-ethnic differences in liver transplant waitlist outcomes in patients with hepatocellular carcinoma before and after recent changes to allocation policy.
Mazur RD; Cron DC; Goldberg DS; Yeh H; Dageforde LA
Clin Transplant; 2024 Jun; 38(6):e15365. PubMed ID: 38804605
[TBL] [Abstract][Full Text] [Related]
3. Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States.
Shah RH; Chyou D; Goldberg DS
Liver Transpl; 2022 Dec; 28(12):1857-1864. PubMed ID: 35585774
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.
Bernards S; Hirose R; Yao FY; Jin C; Dodge JL; Huang CY; Mehta N
Liver Transpl; 2022 Mar; 28(3):376-385. PubMed ID: 34761847
[TBL] [Abstract][Full Text] [Related]
5. Exception Policy Change Increased the Simultaneous Kidney-Liver Transplant Probability of Polycystic Disease in the Centers With High Median MELD at Transplantation.
Miyake K; Kim DY; Chau LC; Trudeau S; Kitajima T; Wickramaratne N; Shimada S; Nassar A; Yoshida A; Abouljoud MS; Nagai S
Transplantation; 2024 Jul; 108(7):1632-1640. PubMed ID: 38548699
[TBL] [Abstract][Full Text] [Related]
6. Waitlist Outcomes for Exception and Non-exception Liver Transplant Candidates in the United States Following Implementation of the Median MELD at Transplant (MMaT)/250-mile Policy.
Ishaque T; Beckett J; Gentry S; Garonzik-Wang J; Karhadkar S; Lonze BE; Halazun KJ; Segev D; Massie AB
Transplantation; 2024 Mar; ():. PubMed ID: 38548691
[TBL] [Abstract][Full Text] [Related]
7. Racial Disparities in Candidates for Hepatocellular Carcinoma Liver Transplant After 6-Month Wait Policy Change.
Saberi B; Gurakar A; Tamim H; Schneider CV; Sims OT; Bonder A; Fricker Z; Alqahtani SA
JAMA Netw Open; 2023 Nov; 6(11):e2341096. PubMed ID: 37917059
[TBL] [Abstract][Full Text] [Related]
8. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
[TBL] [Abstract][Full Text] [Related]
9. Effects of the implementation of acuity circle policy on waitlist and post-transplant outcomes of liver re-transplantation.
Shimada S; Shamaa T; Ivanics T; Miyake K; Kitajima T; Rizzari M; Yoshida A; Abouljoud M; Moonka D; Nagai S
Clin Transplant; 2023 Jun; 37(6):e14977. PubMed ID: 36951511
[TBL] [Abstract][Full Text] [Related]
10. Changing opportunities for liver transplant for patients with hepatocellular carcinoma.
Zendel A; Watkins R; Moon AM; Gerber DA; Barritt AS; Desai CS
Clin Transplant; 2022 May; 36(5):e14609. PubMed ID: 35137467
[TBL] [Abstract][Full Text] [Related]
11. Waitlist mortality and post-liver transplant outcomes of pediatric patients with hepatocellular carcinoma and hepatoblastoma in the United States.
Wu WK; Ziogas IA; Matsuoka LK; Izzy M; Pai AK; Benedetti DJ; Alexopoulos SP
Pediatr Blood Cancer; 2022 Jan; 69(1):e29425. PubMed ID: 34736292
[TBL] [Abstract][Full Text] [Related]
12. Ethnicity and Insurance-Specific Disparities in the Model for End-Stage Liver Disease Score at Time of Liver Transplant Waitlist Registration and its Impact on Mortality.
Robinson A; Hirode G; Wong RJ
J Clin Exp Hepatol; 2021; 11(2):188-194. PubMed ID: 33746443
[TBL] [Abstract][Full Text] [Related]
13. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
[TBL] [Abstract][Full Text] [Related]
14. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
Goldberg D; French B; Abt P; Feng S; Cameron AM
Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
[TBL] [Abstract][Full Text] [Related]
15. Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States.
Young K; Liu B; Bhuket T; Younossi Z; Saab S; Ahmed A; Wong RJ
J Viral Hepat; 2017 Sep; 24(9):789-796. PubMed ID: 28273387
[TBL] [Abstract][Full Text] [Related]
16. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
Tan EK; Goh BKP; Lee SY; Krishnamoorthy TL; Tan CK; Jeyaraj PR
Transplant Proc; 2018 Dec; 50(10):3564-3570. PubMed ID: 30577239
[TBL] [Abstract][Full Text] [Related]
17. Continuous Risk Score Predicts Waitlist & Post-Transplant Outcomes in Hepatocellular Carcinoma Despite Exception Changes.
Akabane M; McVey JC; Firl DJ; Kwong AJ; Melcher ML; Kim WR; Sasaki K
Clin Gastroenterol Hepatol; 2024 Jun; ():. PubMed ID: 38908731
[TBL] [Abstract][Full Text] [Related]
18. Ethnicity-Specific Differences in Liver Transplant Outcomes Among Adults With Primary Sclerosing Cholangitis: 2005-2017 United Network for Organ Sharing/Organ Procurement and Transplantation Network.
Bayable A; Ohabughiro M; Cheung R; Wong RJ
J Clin Exp Hepatol; 2021; 11(1):30-36. PubMed ID: 33679046
[TBL] [Abstract][Full Text] [Related]
19. Hypoalbuminemia is Associated With Significantly Higher Liver Transplant Waitlist Mortality and Lower Probability of Receiving Liver Transplant.
Ahn J; Sundaram V; Ayoub WS; Frenette C; Wong RJ
J Clin Gastroenterol; 2018; 52(10):913-917. PubMed ID: 29356783
[TBL] [Abstract][Full Text] [Related]
20. Extreme hyponatremia as a risk factor for early mortality after liver transplantation in the MELD-sodium era.
Ivanics T; Leonard-Murali S; Mouzaihem H; Moonka D; Kitajima T; Yeddula S; Shamaa MT; Rizzari M; Collins K; Yoshida A; Abouljoud M; Nagai S
Transpl Int; 2021 Dec; 34(12):2856-2868. PubMed ID: 34580929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
